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Abstract: Background. There are few prospective studies with sufficient duration in time to
evaluate clinical and antibiotic resistance impact of Antibiotic Stewardship Programs
(ASP).
Methods. Descriptive study between January-2012 to December-2017, pre-post-
intervention. An meropenem ASP was initiated in January 2015, in patients who started
treatment with meropenem an infectious diseases physician performed treatment
recommendations to prescribers. Prospective information was collected to evaluate
adequacy of meropenem prescription to local guidelines and to compare results
between cases with accepted or rejected intervention. Analysis was performed to verify
variables associated with intervention acceptance and with any significant change in
meropenem consumption, hospital-acquired multidrug-resistant (MDR) bloodstream
infections (BSIs) and 30-day  all-cause crude death in MDR BSIs.
Results. Adequacy of meropenem prescription and de-escalation from meropenem
treatment to narrower-spectrum antibiotic improved progressively over time, after ASP
implementation (p <0.001). Interventions on prescription were performed in 330
(38.7%) patients without meropenem justified treatment, in 269 intervention was
accepted and in 61 not. Intervention acceptance was associated with shorter duration
of treatment, cost and inpatient days (p<0.05); intervention rejection was not
associated with severity of  patient. During the period 2015-2017, meropenem
consumption decreased compared with 2012-2014 [Rate ratio (RR) 0.67; 95%CI: 0.58-
0.77, p<0.001]). Likewise decreased, hospital-acquired MDR BSIs rate (RR 0.63;
95%CI: 0.38-1.02, p=0,048) and 30-day all-cause crude death in MDR BSIs (RR 0.45;
95%CI: 0.14-1.24, p=0.09), coinciding in time with ASP start-up.
Conclusions. The decrease and better use of meropenem achieved had a sustained
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
clinical, economic and ecological impact, reducing costs and mortality of hospital-
acquired MDR BSIs.
Response to Reviewers: Ferrol, October  16th 2018
To the European Journal of Clinical Microbiology and Infection Diseases  Editorial
Office
Dear Editor,
We appreciate the valuable reviewers´comments for our manuscript “Meropenem
Antimicrobial Stewardship Program: clinical, economic and antibiotic resistance impact”
(EJCM-D-18-00706).
Please, find hereunder our replies to the reviewers´ comments, in a point-by-point
manner.
Page 2, line 3: “The authors introduce a five year screening period here but if I read
correctly there is only two years of detailed follow up int he  end. Two questions: if this
is so then correct the timelines and if this is so, then please state whether two years is
sufficient follow up or whether a longer term would be needed. Rendering the current
paper a bit preliminary ....”
Corresponding author´s response:
Descriptive study between January-2012 and December-2017, pre-post-intervention.
Page 2, Result section: “Somewhere in the text the authors state that the use of
handwashing alcohol increased over the study period. So are there other potential
confounders here? I am also missing the overall antibiotic use in the hospital during the
the study years. How did that evolve? Anything else of relevance that evolved???”
Corresponding author´s response in page 10, lines 1-4
The alcohol-based hand-rub consumption increased progressively from 2012 to 2017,
about 9.9% per year, without there being a significant change in this annual increase
between the pre and post-intervention period. The overall antibiotic use in the hospital
during the study years increased from 94.7 DDD/100 OBDs in 2012-2014 to 105.8
DDD/100 OBDs in 2015-2017.
Page 3, lines 1-6: “Delete, textbook stuff”.
Corresponding author´s response:
Despite what is said in this paragraph is evident, we consider this statement describes
the rationale to justify our work.
Page 5, lines 5-7: “It is OK to exclude double treatments unless it happens very
frequently. Can you quantify this a bit??”
Corresponding author´s response:
Patients who received more than one course of meropenem during their hospitalization
(29 patients) were only included once in the study.
Page 6, lines 14-19: “So if I understand it correctly the authors used the number of
BSIs caused by a restricted set of bacterial species as a proxy for resistance. This
seems very strange to me and should be explained in more detail”.
Corresponding author´s response:
In order to assess the impact on the antibiotic resistance, we analyzed between
January 2012 and December 2017 the evolution of incidence density per 1000 OBDs
of hospital-acquired BSIs produced by the most frequently isolated microorganisms
(coagulase-negative Sthaphylococi excluded): Pseudomonas aeruginosa, Klebsiella
spp, E. coli, Enterobacter spp, Staphyloccoccus aureus and Candida spp, between
2012 and 2017.
Page 8, lines 6-8: “I do not understand this sentences and it seems to be an important
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
one. There seems to be some sort of an omission. Please clarify”.
Corresponding author´s response:
Out of the 852 patients who received treatment with meropenem, in 522 of them the
treatment was considered justified because it was adapted to the local empirical
treatment guidelines; in 330 (38.7%) the treatment was not considered justified and
interventions were performed at the suggestion of appropriate alternative treatment: in
269 (81.5%) of them, the intervention was accepted and in 61 it was not.
Page 9, lines 13-15: “Do I understand correctly, again, that the authors state here that
the "resistant BSIs" went down and the "susceptible BSIs" went up? So with ASP you
prevent a certain category of infections which is then compensated by a set of others?
How would then the overall net reduction for BSI on the whole be? And if that does not
change then where is the economic and medical benefit??”
Corresponding author´s response:
The global incidence of bacteraemia adjusted by 1000 OBDs increased by 3.5% during
the period 2015-2017 vs 2012-2014. The incidence density of candidemia and MDR
BSIs acquired in hospital decreased after ASP start-up in a parallel fashion with the
decrease in use of meropenem (Figures 2, 3). In 2015-2017 hospital-acquired MDR
BSIs rate was 0.084/1000 OBDs vs 0.133 in 2012-2014 (RR 0.63; 95%CI: 0.38-1.02,
p=0.048). Conversely, the incidence density of in-hospital acquired BSIs produced by
non-MDR strains of the same microorganisms under study increased 8% during the
intervention period (RR 1.08; 95%CI: 0.78-1.51), (Table 4).
Page 12, lines 7-8: “Making statements on behaviour is nice but completely out of
scope here. Niceness cannot be quantified easily and prior to making statements as
you do, data would be needed....”
Corresponding author´s response:
On page 8, line 12-13 we have included: “the degree of intervention acceptance varied
according to prescriber (between 29% to 100%) and infection localization”
Our experience and results show that there are some prescribers that are unwilling to
accet interventions, but we consider inappropriate to go deeply in detailing to avoid
causing discomfort among hospital professionals.
Table 1: “There are shiploads of significant differences here that I see hardly explained
in the text .... Are all of these negligable with respect to the effect measured in this
study????”
Corresponding author´s response:
We comment in page 12, line 9-11 that “with our intervention we have decreased the
incidence of hospital-acquired MDR BSIs and associated mortality despite having
increased the total incidence of bacteraemia and global consumption of antibiotics”.
and in page 12, line 22 “but it does not seem that other variables influenced the results
of the study”.
Thank you very much for your time spent on reevaluating our manuscript.
Sincerely yours,
Dr. José Francisco García-Rodríguez
Infectious Diseases Unit. Department of Internal Medicine.
University Hospital of Ferrol, A Coruña, Spain
jose.francisco.garcia.rodriguez@sergas.es
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Background. There are few prospective studies with sufficient duration in time to evaluate clinical 
and antibiotic resistance impact of Antibiotic Stewardship Programs (ASP).  
Methods. Descriptive study between January-2012 and December-2017, pre-post-intervention. An 
meropenem ASP was initiated in January 2015, in patients who started treatment with meropenem 
an infectious diseases physician performed treatment recommendations to prescribers. Prospective 
information was collected to evaluate adequacy of meropenem prescription to local guidelines and 
to compare results between cases with accepted or rejected intervention. Analysis was performed to 
verify variables associated with intervention acceptance and with any significant change in 
meropenem consumption, hospital-acquired multidrug-resistant (MDR) bloodstream infections 
(BSIs) and 30-day  all-cause crude death in MDR BSIs. 
Results. Adequacy of meropenem prescription and de-escalation from meropenem treatment to 
narrower-spectrum antibiotic improved progressively over time, after ASP implementation (p 
<0.001). Interventions on prescription were performed in 330 (38.7%) patients without meropenem 
justified treatment, in 269 intervention was accepted and in 61 not. Intervention acceptance was 
associated with shorter duration of treatment, cost and inpatient days (p<0.05); intervention 
rejection was not associated with severity of patient. During the period 2015-2017, meropenem 
consumption decreased compared with 2012-2014 [Rate ratio (RR) 0.67; 95%CI: 0.58-0.77, 
p<0.001]). Likewise decreased, hospital-acquired MDR BSIs rate (RR 0.63; 95%CI: 0.38-1.02, 
p=0,048) and 30-day all-cause crude death in MDR BSIs (RR 0.45; 95%CI: 0.14-1.24, p=0.096), 
coinciding in time with ASP start-up.  
Conclusions. The decrease and better use of meropenem achieved had a sustained clinical, 
economic and ecological impact, reducing costs and mortality of hospital-acquired MDR BSIs. 
  
Keywords. Antimicrobial stewardship; multidrug-resistant; hospital infections; bloodstream 
infections; carbapenems. 
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Introduction. Antibiotics are effective drugs in reducing morbidity and mortality of patients, but 
they have ecological effects such as the appearance and spread of bacterial resistance. Bacterial 
resistance to antibiotics is a global problem of such magnitude that more than 163 countries 
committed themselves at the UN General Assembly to put in place measures to deal with it (1). 
Among the measures proposed are the implementation of antimicrobial stewardship programs 
(ASP).   
ASP are quality improvement programs that include heterogeneous interventions, such as auditing, 
restriction of specific antibiotics, restriction of treatment duration, and antibiotic cycling or mixing 
(2). The implementation of these measures has shown to significantly reduce use of antibiotics and 
hospital costs (3,4), but few studies refer to the impact in clinical outcome (5), antibiotic resistance 
(6, 7, 8) or incidence of Clostridium difficile infection (9,10). The interventions are generally more 
effective in prospective studies, but there are few studies of this type that cover the entire hospital 
and with a duration long enough in time to evaluate its effect. In addition, the implementation of 
ASP should be recommended not only on the basis of well-known cost benefits, but also  because of 
the most relevant clinical advantages for patients (11). 
The implementation of ASP requires the provision of resources not always available, and it is 
necessary to prioritize those interventions that may have greater impact. The aim of our study is to 
evaluate the impact of  ASP implementation on the prescription of meropenem in a 350-bed 
hospital over 3 years. 
Methods.  
Study design. Descriptive study between January 2012 and December 2017, pre-post-intervention. 
We analysed the evolution of adequacy of meropenem prescription and clinical impact, antibiotic 
consumption and the incidence of bloodstream infections acquired in the hospital.  
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Setting. The study was conducted in a 350-bed teaching hospital from 2015 to 2017. The hospital 
has one ICU with 10 beds and does not have transplant programs. The infection prevention and 
control program was the same throughout the study. From 2012 an infectious diseases (ID) 
physician performed prospective active surveillance of all episodes of bloodstream infections 
(BSIs) (12). 
Intervention. A multidisciplinary team of professionals was constituted in the University Hospital 
of Ferrol for ASP implementation, at the end of 2014. Local guidelines for empiric antibiotic 
treatment were developed and are accessible on our intranet via an icon on every hospital computer 
desktop. Between January 2015 and December 2017 a prospective follow-up of meropenem use 
was performed. It was decided to start monitoring meropenem use because it was the broadest 
spectrum carbapenem in our hospital, in a resource-limited setting for ASP implementation.  
Ertapenem is available with indication for the treatment of infections caused by extended-spectrum 
β-lactamases producing enterobacteriaceae (ESBLs) and we do not have other carbapenems. 
Patients who started treatment with meropenem were selected every day using a drug dispensation 
program (all hospital units, except ICU). Prescriber´s counseling measures were performed the first 
day of prescription and a course on optimization of antibiotics use, targeted at trainee pharmacists 
and physicians, as well as at primary care physicians, was carried out each year. An annual ASP 
update was presented at a hospital general clinical session. 
An ID physician was released 6 hours a week to perform active surveillance. For each case, the 
electronic medical record was reviewed by ID physician and antibiotic treatment recommendations 
to prescribers were given, on a face-to-face or telephone conversation basis, or through an 
electronic medical record. Additional differential diagnoses, investigations, and adjunctive therapy 
(for example, removal of urinary or central venous catheters (CVC), drainage of infected 
collections) were also recommended. Adherence to or rejection of the recommendations were 
assessed by ID physician 24 and 48 hours post-recommendation as part of the ASP workflow. 
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Prospective and protocolized information was collected for each case: site of infection, place of 
acquisition, clinical situation of patient, comorbidity (Charlson index), adequacy of treatment to 
hospital guideline, acceptance of intervention, treatment de-escalation, days of treatment, clinical 
evolution, collateral damage, inpatient days, treatment cost and readmission. Patients who received 
more than one course of meropenem during their hospitalization (29 patients) were only included 
once in the study. The data was obtained by monitoring the information recorded in the electronic 
medical record. This study was approved by the Institutional Review Boards and Ethic Committee . 
 
Adequacy of treatment. Cases with meropenem prescription during the last 4 months of 2014 were 
retrospectively reviewed. This sample of the pre-intervention period was used to compare with 
patients who started treatment with meropenem during the intervention period, to know if the local 
guidelines adequacy of meropenem prescription and antibiotic treatment de-escalation improved 
since ASP implementation. Appropriate treatment with meropenem was considered when it was 
prescribed in patients with: 1. Severe sepsis (13); 2. history of ESBLs colonization; or 3. hospital-
acquired infection in which a broad-spectrum antibiotic treatment was considered necessary. De-
escalation antibiotic treatment was defined as the change from meropenem to narrower-spectrum 
antibiotic over the longer course of the treatment.  
Clinical and economic impact. To know the clinical impact of the intervention in cases in whom 
treatment with meropenem was not justified during 2015-2017, a comparison was made between 
the cases with accepted intervention (modification of antibiotic treatment) and cases with rejected 
intervention (they continued with meropenem) in their clinical evolution, days of antibiotic 
treatment, collateral damage, cost of treatment, inpatient days, and hospital readmission. Death was 
attributable to infectious process if it occurred within 7 days after starting treatment with 
meropenem (or days later if the event was directly related to a persistent infection, eg, abscesses, 
endocarditis) and all-cause crude death was defined over the month follow-up. 30-day infection-
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related and all-cause readmission were defined as readmission occurring within 30 days from 
discharging of current admission.  
The impact on antibiotic treatment cost during the 3-year follow-up was estimated based on the 
difference of the laboratory price between treatment with meropenem and proposed antimicrobial in 
the intervention, when it was accepted, and assuming the same duration of treatment. The cost 
savings per inpatient days were made comparing the inpatient days post-intervention between cases 
with accepted intervention and cases with rejected intervention. The inpatient days potentially 
avoided in cases with accepted intervention were multiplied by the official cost of one day hospital 
stay (528 €).  
During the study period, antibiotic consumption was assessed as Defined Daily Doses (DDD) per 
100 occupied bed days (OBDs) (14). The repercussion on the use of antibiotics was made 
comparing the DDD/100 OBDs between the years 2012 and 2017.  
Impact on resistances. In order to assess the impact on the antibiotic resistance, we analyzed 
between January 2012 and December 2017 the evolution of incidence density per 1000 OBDs of 
hospital-acquired BSIs produced by the most frequently isolated microorganisms (coagulase-
negative Sthaphylococi excluded): Pseudomonas aeruginosa, Klebsiella spp, E. coli, Enterobacter 
spp, Staphyloccoccus aureus and Candida spp, between 2012 and 2017. 
Hospital-acquired BSIs were defined as those diagnosed from blood cultures obtained ≥48 hours 
after hospital admission or in those cases when, even occurring in the first 48 hours, the patient had 
been hospitalized during the previous two weeks. Patients with a recurrent isolation of the same 
microorganisms were considered as a unique episode of BSI unless the sample was obtained one 
month after the last positive blood culture.  
The identification of blood isolates and the determination of resistance to antibiotics were 
performed according to Clinical Laboratory Standard International (CLSI). The MDR 
 7 
categorization was applied for extended-spectrum β-lactamases or carbapenemase-producing 
Enterobacteriaceae, all isolates of methicillin-resistant S. aureus and Candida spp, and all 
Pseudomomas aeruginosa and A. baumannii strains fulfilling the German Society for Hygiene and 
Microbiology criteria for MDR organisms (15).   
Colonization was defined as the isolation of the organism from a non sterile site in the absence of 
symptoms of infection, and infection when patient's doctor  prescribed treatment.   
 
Statistical analysis. A descriptive and comparative study of the variables was performed. 
Quantitative variables are reported as means ± standard deviations, and categorical as  frequencies 
(%). Variables were compared between groups using Chi-square test or Fisher exact test for 
categorical variables, Student t-test or Mann-Whitney U for continuous variables, as appropriate. 
Logistic regression was performed to evaluate the predictors of intervention acceptance. 
Associations between the variables were expressed as odds ratios (ORs) and 95% confidence 
intervals (CIs). Resistance rates per 1000 OBDs of in-hospital acquired BSIs with a 95%CI and 
rates of mortality were calculated as Poisson event  rates, and compared by testing for homogeneity 
of rates. Statistical analysis was performed using SPSS software version 19. All tests were 2-tailed, 
a P values < 0.05 was regarded as statistically significant.  
 
Results 
Adequacy of treatment. During the last 4 months of 2014, 150 patients received treatment with 
meropenem and between 2015-2017, 852 patients received it. The indication of justified treatment 
with meropenem progressively improved over time from 47.3% in 2014 to 76.8% in 2017 (p 
<0.001), without significant changes in the characteristics of the patients (Figure 1). De-escalation 
from meropenem treatment to narrower-spectrum antibiotic improved progressively after ASP 
implementation, from 28% in 2014 to 58.8% in 2017 (p<0.05).  
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Clinical and economic impact. Between 2015 and 2017, 852 patients received treatment with 
meropenem, of which 565 were male and 287 female; age 68.4 ± 15.9 years (range 1-96 years). The 
sites of infection were: urinary 334, abdominal 219, pulmonary 187, skin and soft tissue 42, febrile 
neutropenia 20, intravascular catheter 26, other 24. Place of infection acquisition: hospital onset 363, 
healthcare-associated 328 and community-associated 161.  
Out of the 852 patients who received treatment with meropenem, in 522 of them the treatment was 
considered justified because it was adapted to the local empirical treatment guidelines; in 330 
(38.7%) the treatment was not considered justified and interventions were performed at the 
suggestion of appropriate alternative treatment: in 269 (81.5%) of them, the intervention was 
accepted and in 61 it was not. 
The clinical characteristics of patients were similar between patients with and without acceptance of 
ASP recommendations, although the degree of intervention acceptance varied according to 
prescriber (between 29% to 100%) and infection localization (Table 1). The localizations of 
infection in urine or abdomen accounted for 61% of accepted interventions. By multivariate 
analysis, pulmonary infection (OR 0.21; 95%CI: 0.09-0.45) and abdominal infection (OR 0.25; 
95%CI: 0.12-0.50) were associated with lower acceptance of the intervention; the patient 
comorbidity (OR 0.98; 95%CI: 0.88-1.08) or the presence of severe sepsis (OR 0.45; 95%CI: 0.16-
1.28) were not associated with the degree of acceptance of the intervention. 
There were no significant differences between cases with accepted intervention and cases with 
rejected intervention in clinical evolution or collateral damage (Table 2). The development of 
colonization or infection with yeast was lower in cases with accepted intervention. The Charlson 
index was similar throughout the intervention period and was higher in patients who died: 7.2 ± 2.2 
vs 5 ± 2.8, p<0.001. 
The acceptance of the intervention was associated with shorter duration of antibiotic treatment and 
inpatient days (Table 3). The duration of antibiotic treatment in the total series did not decrease 
significantly; in urine infection decreased from 9.4 ± 8.2 days in 2015 to 8.1 ± 6.6 in 2017, and 
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decrease was significant in treatment of  wound infection in abdominal surgery: 22.8 ± 16.3 days in 
2015 to 13.6 ± 8.3 in 2017, p<0.05.  
The 269 patients in whom the intervention was accepted presented 5.9 inpatient days post-
intervention less than cases with rejected intervention, and it was calculated that 1,587 days of 
hospital stay were saved. The estimated cost savings was 866,915.93 € (28,979.93 € in 
antimicrobials and 837,936 €  in 1,587 days of hospital stay potentially-avoided). 
Coinciding in time with the start-up of ASP, there was a 33% decrease in the consumption of 
meropenem during the intervention period with respect to the years 2012-2014 (RR 0.67; 95%CI: 
0.58-0.77, p<0.001), with increase in cefepime consumption (1.2 DDD/100 OBDs in 2012-2014 vs 
2.1 in 2015-2017) and stabilisation of ciprofloxacin and piperacillin-tazobactam consumption 
(Figure 2); ceftazidime consumption decreased by 4.7% and ertapenem decreased by 3.1%. 
 
Impact on resistances. The global incidence of bacteraemia adjusted by 1000 OBDs increased by 
3.5% during the period 2015-2017 vs 2012-2014. The incidence density of candidemia and MDR 
BSIs acquired in hospital decreased after ASP start-up in a parallel fashion with the decrease in use 
of meropenem (Figures 2, 3). In 2015-2017 hospital-acquired MDR BSIs rate was 0.084/1000 
OBDs vs 0.133 in 2012-2014 (RR 0.63; 95%CI: 0.38-1.02, p=0.048). Conversely, the incidence 
density of in-hospital acquired BSIs produced by non-MDR strains of the same microorganisms 
under study increased 8% during the intervention period (RR 1.08; 95%CI: 0.78-1.51), (Table 4).  
To assess if there were other changes in hospital activity that could have contributed to the decrease 
in the incidence density of hospital-acquired MDR BSIs we monitored some complexity indicadors 
(16) (Table 4). In the period 2015-2017 compared to 2012-2014 increased: the number of blood 
cultures performed per 1000 OBDs (RR 1.14; CI95%: 1.1-1.17, p<0.001), the prevalence of CVC 
use (4.56% vs 2.29%, p = 0.004), catheter-associated BSIs rate (RR 1.08; 95%CI: 0.85-1.38) and 
the consumption of parenteral nutrition  (RR 1.13; 95%CI: 1.08-1.18, p<0.001); whereas antifungal 
consumption decreased by 5%  (RR 0.95; 95%CI: 0.90-0.99, p=0.04). 
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The alcohol-based hand-rub consumption increased progressively from 2012 to 2017, about 9.9% 
per year, without there being a significant change in this annual increase between the pre and post-
intervention period. The overall antibiotic use in the hospital during the study years increased from 
94.7 DDD/100 OBDs in 2012-2014 to 105.8 DDD/100 OBDs in 2015-2017. 
Patients with in-hospital acquired MDR BSIs had higher mortality than patients with non-MDR 
BSIs: death associated with infection 16.3% vs 6.9% (p=0.008) and all-cause crude death 26.3% vs 
18.3% (p=0.09). The incidence density of infection-associated mortality for in-hospital acquired 
MDR BSIs decreased during the intervention period by 45% (0.012 / 1000 OBDs vs 0.022 in 2012-
2014) (RR 0.52; 95%CI: 0.11-1.95) and the incidence density of all-cause crude death decreased by 
56.4% (0.017 / 1000 OBDs  vs 0.039 in 2012-2014) (RR 0.45; 95%CI: 0.14-1.24, p=0.09), figure 2.  
The death rate for hospital acquired bacteraemias produced by non-MDR microorganisms increased  
over time: infection associated mortality 0.047 / 1000 patients-days  in 2012-2014 to 0.058 in 2015-
2017 (RR 1.23; 95%CI: 0.64-2.34, p=0.64); all-cause crude mortality 0.12 / 1000 patients-days in 
2012-2014 to 0.16  in 2015-2017 (RR 1.28; 95%CI: 0.86-1.91, p=0.26). 
Throughout the study period, we did not have bacteraemia due to carbapenemase-producing 
microorganisms nor vancomycin-resistant Enterococcus spp, and the incidence of Clostridium 
difficile-associated diarrhoea remained stable about  0.2/1000 patients-days. 
Discussion  
The care of patients with suspected infections is complex and metrics to assess ASP impact are 
poorly defined (17, 18). The implementation of our ASP improved the prescription of meropenem 
and decreased its use, as well as progressively increased the frequency of de-escalation to narrower-
spectrum antibiotic. The acceptance of the intervention made by ID physician decreased days of 
treatment, cost and inpatient days, without negative impact on patient safety.  
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Some studies reported shorter length of admission in the intervention group than control group and 
lower mortality (19). Ng et al (20) reported a significant difference in length of stay between the 
periods before and after ASP implementation with no difference in mortality, like other studies (21-
25). Tedeschi et al. achieved a decrease in meropenem use with no increases in mortality or length 
of stay, and with a decrease in antimicrobial resistance patterns in a rehabilitation hospital (26).  
Only one study assessed incidence of collateral damage following carbapenem de-escalation in a 
ESBLs endemic setting, and reported fewer adverse reaction in de-escalated group, shorter duration 
of carbapenem use and less development of resistances (27). There are no prospective studies 
outside the ICUs that analyze the development of infection caused by yeast during antibiotic 
treatment, and only one prospective study refers to readmissions after discharging, without 
differences between patients with or without acceptance of ASP recommendation (28). A study with 
educational and semi-restrictive measures, carried out in a carbapenem-resistant Klebsiella 
pneumoniae endemic 1200-bed adult care hospital, showed a decrease in antibiotics consumption 
and incidence of Klebsiella pneumoniae bacteremia, without changes in candidemia or consumption 
of antifungal (29).  
In our hospital the incidence of Clostridium difficile-associated diarrhoea is low and remained 
stable and our results show a decrease in the incidence of hospital-acquired candidemia and MDR 
BSIs; this decrease was parallel to the decrease in meropenem consumption and to decrease in the 
duration of antibiotic treatment for wound infection in abdominal surgery (30). Candidemia is the 
fourth cause (4.9%) of hospital-associated BSIs in our hospital and is more frequent in the general 
surgery department (38.5%). The decrease in the duration of antibiotic treatment, the increase in de-
escalation from meropenem to narrower-spectrum antibiotics and the lesser development of 
colonization caused by yeast in patients in whom the intervention was accepted, all of them have 
undoubtedly contributed to decrease in candidemia. The decrease in the incidence of yeast infection 
has occurred despite the increase in the number of surgical interventions, the use of CVC and 
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parenteral nutrition. This is reflected in decrease of antifungal drugs use during the intervention 
period (31, 32). 
We have observed a decrease in MDR BSIs-associated mortality incidence after starting-up the 
ASP, as in another study with multifaceted educational intervention (8). The ASPs are underfunded 
and it is necessary to prioritize for undertaking those interventions that may have a greater impact 
(33, 34). In a resource-limited setting, we decided to follow the use of  carbapenems because they 
are the antibiotics with the broadest antibacterial spectrum and with a rapid induction of beta-
lactamases, and with our intervention we have decreased the incidence of hospital-acquired MDR 
BSIs and associated mortality despite having increased the total incidence of bacteraemia and  
global consumption of antibiotics. 
The results obtained in our study are undoubtedly due to the good acceptance of the interventions 
by the prescribers, higher than the median change in antibiotic prescribing (42.3%) for the 
persuasive interventions described in the literature (35, 36). This should certainly be due to the fact 
that interventions were performed in a medium-sized hospital and with good interpersonal 
communication among professionals who also work in infection prevention and control (37, 38). 
The intervention rejection level was not associated with the severity or comorbidity of the patient 
and it seemed to be more in relation with clinicians’ attitudes in different hospitalization units (39). 
It is also possible that sensitizacion measures on resistance to antibiotics conveyed through the 
media and training courses could have played some role over the general population and physicians 
(40), but it does not seem that other variables influenced the results of the study. 
Our achieved cost savings are much higher than ASP cost (an ID physician was released 6 hours a 
week) warranting the financing of ASPs with more resources to expand the program in the hospital 
to other antibiotics (26, 35, 36), towards primary care (7, 41) and  long-term care settings (42).  
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The strength of our study is the large number of variables analyzed and prospective data collection 
over 3 years to evaluate the impact of ASP, and our results prove that ASP is cost-effective. We 
assessed compliance with local guidelines as the standard for appropriate therapy to reduce the 
more subjective method of expert opinion-based definitions (18).  
Our study has several limitations. The study was restricted to those wards with electronic 
medication dispensing system (all the hospital except ICU unit), but patients transferred from the 
ICU to other hospitalization units and who were receiving treatment with meropenem were also 
followed. The MDR BSIs acquired in ICU between 2012-2017 accounted for 7.8% of hospital 
bacteraemia, without significant differences between pre and post intervention period, and we 
believe that the activity of this service has not influenced our results.  
The sample size does not allow a regression or time series analysis to provide good stability to the 
results obtained, but they reflect the changes in consumption of meropenem and in the incidence of 
in-hospital MDR BSIs and mortality, after starting the ASP; these changes in trend seem to be due 
to our intervention and not to changes in healthcare during the study period. The single-center 
design limits the possibility of generalizing our results to other hospitals, and including preferred 
methods such as control groups or randomization was impractical.  
In conclusion, the results of this study show that the decrease and better use of meropenem achieved 
by our ASP program had a sustained clinical, economic and ecological impact, reducing costs and 
mortality of hospital-acquired MDR BSIs. 
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   Table 1. Baseline Demographic and Clinical Characteristics of Patients with 
               and without Acceptance of ASP Recommendations. Years  2015-2017. 
  Variables Intervention 
accepted n=269 
Intervention 
rejected n=61 
 
p 
 Male gender, n (%) 174 (64.7) 40 (65.6) 1 
 Median age ± SD, years (range) 66.6 ± 15.7 (10-96) 
 
66.2 ± 19 (6-95) 0.87 
 Charlsonʼs comorbidity score, 
  Median ± SD, (range) 
4.98 ± 3 (0-13.6) 5.06  ± 2.89 (0-12) 0.84 
 Neutropenia, < 500/mL 5 (1.9) 2 (3.3)  0.62 
 Severe sepsis   17 (6.3) 6 (9.8) 0.4 
 Site of infections, n (%) 
   Pulmonary   44 (16.4) 19 (31.1) 0.01 
   Abdominal 74 (27.5) 28 (45.9) 0.009 
   Skin / soft tissue 15 (5.6) 1 (1.6) 0.32 
   Urinary 90 (33.4) 10 (16.4)  0.009 
   Other 46 (17.1) 3 (4.9) 0.016 
  Acquisition place of infection 
   Hospital onset  85 (31.6) 24 (39.3) 0.29 
   Healthcare-associated 93 (34.6) 24 (39.3) 0.55 
   Community-associated 91 (33.8) 13 (21.3) 0.07 
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Table 2. Clinical Results of Patients with and without Acceptance of ASP   
               Recommendations. Years  2015-2017. 
 
   Variables Intervention 
accepted n=269 
Intervention 
rejected n=61 
 
p 
  Healing 239 (88.8%) 51 (83.6%) 0.28 
  Death caused by infection 12   (4.5%) 6 (9.8%) 0.11 
  All-cause crude death 30   (11.2%) 10   (16.40%) 0.28 
  Readmission in a month 10#  (3.7%) 3*  (4.9%) 0.71 
  Adverse effects 28   (10.4%) 5   (8.2%) 0.81 
  Phlebitis 44 (16.4%) 8 (13.1%) 0.70 
  Development of   
  resistance to treatment 
6   (2.2%) 0   (0%) 0.60 
  Diarrhea caused by C. difficile 6   (2.2%) 1   (1.6%) 1 
  Colonization-Infection 
  with Candida spp 
30 (11.2%) 9 (14.8%) 0.51 
#4 relapses of the infection, 6 due to other causes. 
* No relapse of infection, due to other causes. 
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Table 3. Economic Results, Patients with and without Acceptance of ASP  
              Recommendations. Years 2015-2017.  
 
Variables 
Intervention 
accepted n=269 
Intervention 
rejected n=61 
p 
Days of antibiotic treatment 11 ± 10.1 13.8 ± 9 0.05 
Cost of antibiotic treatment 108.3 ± 371.2 202.4 ± 504.8 0.09 
Total inpatient days, X±SD 17.6 ± 16.8 26.2 ± 23.6 0.001 
Inpatient days post-intervention,  X±SD 12.6 ± 14.4 18.55 ± 20.5 0.009 
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Table 4. Potencial Changes in Healthcare During the Study Period by Year 
Healthcare Variable 2012 2013 2014 2015 2016 2017 
Nº of patients admitted 14721 14615 14979 14867 14852 15248 
Nº of inpatient days 119885 121181 119615 116588 114072 114864 
Blood cultures perforrmed, No. 3242 3340 2985 3003 3419 3074 
Nº blood cultures / 1000 OBDs 27.04 27.56 24.95 25.76 29.97 26.76 
Hospital-acquired no-MDR 
BSIs / 1000 OBDs 
 
0.69 
 
0.76 
 
0.71 
 
0.69 
 
0.76 
 
0.88 
Intravascular catheter-associated 
BSIs / 1000 OBDs  
0.27 0.39 0.48 0.35 0.42 0.46 
Surgical procedures, No. 8848 9285 8836 9148 9352 9151 
Case mix index 1.51 1.54 1.56 1.57 1.58 1.59 
Parenteral nutrition units,  
No. / 100 OBDs 
2.91 3.87 3.95 4.61 4.13 3.40 
Consumption of antifungals,  
DDD / 100 OBDs 
2.91 3.84 3.08 3.49 3.31 2.55 
MDR: multidrug-resistant. BSIs: bloodstream infections. OBDs: occupied bed days. 
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